SPATA31C2

Across TCGA pan-cancer cohorts, SPATA31C2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPATA31C2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SPATA31C2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA31C2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LIHC, SKCM, and HNSC are the cancer types where SPATA31C2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.146	0.692	<.001	36	view →
SKCM	DFS	Median	III,IV	0.237	0.665	.003	15	view →
HNSC	OS	Median	All	0.851	0.347	.026	8	view →
LUSC	OS	Median	III,IV	0.145	0.672	.003	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPATA31C2–LIHC (OS)

Open the LIHC breakdown →